Ivabradin Hcs (Ivabradine)

Ivabradine selectively blocks the If (funny) current in the sino‑atrial node, the primary pacemaker of the heart. Inhibition of this mixed sodium‑potassium inward current slows the spontaneous depolarisation of pacemaker cells, producing a controlled reduction in heart rate without decreasing myocardial contractility.

The dosage of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerability. Typical regimens start with a low dose that may be titrated upward, but the exact amount and schedule must be determined by a qualified healthcare professional.

Safety data for ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential maternal benefit justifies any possible risk to the fetus, and breastfeeding mothers should consult their physician before use.

To request Ivabradin Hcs, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also decrease contractility, whereas ivabradine selectively inhibits the If current without affecting contractility. Ivabradine is often considered when beta‑blockers are contraindicated or insufficient.

Store Ivabradin Hcs at ambient temperature below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Ivabradin Hcs is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed, or chewed. Dosing times are generally spaced evenly, often twice daily, but the exact schedule is set by the prescribing clinician.

The most serious adverse events include severe bradycardia, atrial fibrillation, and symptomatic hypotension. Patients should be instructed to report any unusually slow heartbeat, faintness, dizziness, or palpitations promptly, as these may require medical evaluation or dose adjustment.

Ivabradine is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or permanent atrial fibrillation. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.